Does Lurbinectedin Interact with Warfarin?
Lurbinectedin (brand name Zepzelca), an antineoplastic agent for small cell lung cancer, moderately inhibits CYP2C9, the primary enzyme metabolizing the S-enantiomer of warfarin, a vitamin K antagonist anticoagulant [1][2]. This inhibition reduces warfarin clearance, potentially raising its plasma levels and increasing bleeding risk.
Mechanism of Interaction
Lurbinectedin acts as a time-dependent inhibitor of CYP2C9 in vitro, with IC50 values indicating moderate potency (e.g., 1.5 μM for S-warfarin formation) [3]. Warfarin is chiral: the more potent S-warfarin is CYP2C9-dependent (90% metabolism), while R-warfarin uses CYP1A2, CYP3A4, and others. Inhibition primarily affects S-warfarin, prolonging INR and anticoagulant effect [1][4].
No direct in vivo studies test lurbinectedin-warfarin coadministration, but product labeling warns of this interaction based on vitro data [2].
Clinical Recommendations
Avoid coadministration if possible. If unavoidable:
- Monitor INR frequently, starting before and 1 week after lurbinectedin initiation.
- Adjust warfarin dose downward as needed.
- Consider alternatives like low-molecular-weight heparin [2][5].
Related Drug Interactions and Patient Risks
Lurbinectedin also inhibits CYP3A4 weakly and induces it at higher doses, but warfarin impact centers on CYP2C9 [3]. Patients on warfarin face heightened bleeding risks (e.g., GI hemorrhage), especially with lurbinectedin's thrombocytopenia side effect [2]. Elderly patients or those with liver impairment are at higher risk due to altered CYP activity [4].
| Enzyme | Lurbinectedin Effect | Warfarin Relevance |
|--------|----------------------|--------------------|
| CYP2C9 | Moderate inhibitor | ↑ S-warfarin levels, ↑ INR |
| CYP3A4 | Weak inhibitor/inducer | Minor on R-warfarin |
| CYP1A2 | No effect | No impact |
Evidence from Trials and Labeling
Phase 2 trials (e.g., PM14-501) noted no warfarin cases but flagged CYP interactions [6]. FDA label (updated 2023) classifies it as moderate interaction per University of Liverpool algorithm [2][5].
Sources
[1] FDA Zepzelca Label
[2] FDA Zepzelca Label (Drug Interactions)
[3] Clin Pharmacol Ther (2020) - CYP Inhibition Profile
[4] StatPearls - Warfarin Metabolism
[5] Liverpool HEP Interactions
[6] Lancet Oncol (2020) - Lurbinectedin Trials